Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Receivables (2019 - 2024)

Pliant Therapeutics (PLRX) has disclosed Receivables for 6 consecutive years, with $2.3 million as the latest value for Q4 2024.

  • Quarterly Receivables fell 23.19% to $2.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2024, down 23.19% year-over-year, with the annual reading at $2.3 million for FY2024, 23.19% down from the prior year.
  • Receivables for Q4 2024 was $2.3 million at Pliant Therapeutics, down from $3.0 million in the prior quarter.
  • The five-year high for Receivables was $18.6 million in Q4 2020, with the low at $1.6 million in Q3 2021.
  • Average Receivables over 5 years is $4.5 million, with a median of $2.7 million recorded in 2021.
  • The sharpest move saw Receivables plummeted 87.17% in 2021, then soared 391.2% in 2022.
  • Over 5 years, Receivables stood at $18.6 million in 2020, then tumbled by 87.17% to $2.4 million in 2021, then dropped by 16.79% to $2.0 million in 2022, then surged by 51.13% to $3.0 million in 2023, then dropped by 23.19% to $2.3 million in 2024.
  • According to Business Quant data, Receivables over the past three periods came in at $2.3 million, $3.0 million, and $2.0 million for Q4 2024, Q4 2023, and Q3 2023 respectively.